2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2020
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Alcohol Clinical And Experimental Research 2020, 45: 15-24. PMID: 33190310, PMCID: PMC7855436, DOI: 10.1111/acer.14514.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesTreatment seekersNontreatment seekersExpensive clinical trialsPatient populationAlcohol administrationClinical trialsMedication effectsClinical conditionsMedication developmentMedicationsHeavy drinkersMedication experimentsLaboratory screeningClinical realityAdministration guidelinesScreening researchDevelopment pipelineLaboratory studiesRiskGuidelinesParticipantsPharmacotherapyPopulationEthical guidelines
2018
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review
Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal Of Substance Use And Addiction Treatment 2018, 99: 32-43. PMID: 30797392, PMCID: PMC6391743, DOI: 10.1016/j.jsat.2018.12.003.Peer-Reviewed Original ResearchConceptsIllicit opioid useOpioid useEffectiveness of medicationsHealth risk behaviorsTreatment engagementNaltrexone studiesQuasi-experimental studyRisk behaviorsCommunity substanceInjection drug useCorrectional settingsObservational studyMethadonePubMed databaseDrug useSystematic reviewMedicationsJail settingsConsistent findingBuprenorphineRCTsUse of MATIndividual reviewsTreatmentMeta-analytic summaryEffects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkers
2015
Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration
Lechner WV, Knopik VS, McGeary JE, Spillane NS, Tidey JW, McKee SA, Metrik J, Leventhal AM, Rohsenow DJ, Kahler CW. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration. Nicotine & Tobacco Research 2015, 18: 632-636. PMID: 26092968, PMCID: PMC5896808, DOI: 10.1093/ntr/ntv136.Peer-Reviewed Original ResearchConceptsA118G polymorphismG polymorphismOPRM1 geneAlcohol administrationG carriersG alleleRepeated-measures design studyA118G genotypeG allele carriersDose of alcoholVNTR polymorphismMean age 39.2Greater increaseSmoking cessationAge 39.2Allele carriersCigarette cravingG genotypeHigh doseAlcohol consumptionHeavy drinkersThree-sessionDRD4 geneHeavy drinkingVNTR genotype
2008
Developing human laboratory models of smoking lapse behavior for medication screening
McKee SA. Developing human laboratory models of smoking lapse behavior for medication screening. Addiction Biology 2008, 14: 99-107. PMID: 18855800, PMCID: PMC2732001, DOI: 10.1111/j.1369-1600.2008.00135.x.Peer-Reviewed Original ResearchConceptsMedication screeningHuman laboratory modelSmoking behaviorMedication developmentSubsequent ad libitum smokingAd libitum smokingDrug Administration approvalSelf-administration sessionsMedication signalsCessation medicationsLapse behaviorAdministration approvalFirst cigaretteAbstinence outcomesQuit attemptsSmoking relapseUS FoodSmokingSmokersRelapseImportant targetTranslational workCigarettesScreeningMechanistic evaluationDose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTXCorrespondence of Interactive Voice Response (IVR) Reports of Nicotine Withdrawal, Craving, and Negative Mood with Questionnaire Ratings
Toll BA, Cooney JL, McKee SA, O'Malley SS, Cooney NL. Correspondence of Interactive Voice Response (IVR) Reports of Nicotine Withdrawal, Craving, and Negative Mood with Questionnaire Ratings. Nicotine & Tobacco Research 2008, 10: 1057-1064. PMID: 18584469, PMCID: PMC2791461, DOI: 10.1080/14622200802097498.Peer-Reviewed Original ResearchConceptsNicotine withdrawalDepressive symptomsSmoking cessation trialCessation trialDaily smokersInteractive voice response systemVoice response systemDaily assessmentCravingWeeksNegative moodWithdrawalSymptomsPaper questionnaireQuestionnaire ratingsReportFuture studiesQuestionnaireIVR systemMoodDaysSample sizeDaily reportsSmokersSmoking
2007
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.
Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & Tobacco Research 2007, 9: 597-605. PMID: 17454716, PMCID: PMC2527736, DOI: 10.1080/14622200701239662.Peer-Reviewed Original ResearchConceptsMedication Adherence QuestionnaireCigarette smokersNicotine patchAdherence QuestionnaireMedication adherenceNicotine patch useSmoking cessation outcomesPill-taking behaviorSample of smokersDrug plasma levelsBrief screening toolNonadherence factorsMedication useUnintentional nonadherencePlasma levelsCessation outcomesClinical trialsTreatment outcomesDrug levelsPredictive validitySmokersMAQ scoresNonadherenceScreening toolFactor 1Smoke and mirrors: Magnified beliefs that cigarette smoking suppresses weight
White MA, McKee SA, O'Malley SS. Smoke and mirrors: Magnified beliefs that cigarette smoking suppresses weight. Addictive Behaviors 2007, 32: 2200-2210. PMID: 17428615, PMCID: PMC1993360, DOI: 10.1016/j.addbeh.2007.02.011.Peer-Reviewed Original ResearchConceptsSmoking Consequences Questionnaire-AdultWeight concernsWeight-concerned smokersAbility of smokingControl scoresBingeing Severity ScaleWeight-concerned individualsEffectiveness of smokingBody dissatisfactionLoss of controlActual weight gainMagical thinkingExaggerated beliefsPrevious quit attemptsSmoking cessationWeight gainQuit attemptsWeight control strategiesCessation trialTemporary abilitySuppress body weightFood rulesCurrent studyPerceived RiskBeliefsNaltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol‐Dependent Women: A Randomized Controlled Trial
O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R. Naltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol‐Dependent Women: A Randomized Controlled Trial. Alcohol Clinical And Experimental Research 2007, 31: 625-634. PMID: 17374042, DOI: 10.1111/j.1530-0277.2007.00347.x.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAlcohol DrinkingAlcoholismAttitudeBody Mass IndexBulimiaCognitive Behavioral TherapyCombined Modality TherapyDepressionFeeding and Eating DisordersFemaleGamma-GlutamyltransferaseHumansNaltrexoneNarcotic AntagonistsPsychiatric Status Rating ScalesTreatment OutcomeConceptsCognitive Behavioral Coping Skills TherapyAlcohol-dependent womenEfficacy of naltrexoneCoping skills therapyAlcohol dependenceOutpatient research clinicSkills therapyCo-occurring psychiatric conditionsEating Disorder FeaturesDSM-IV criteriaPercentage of participantsPrimary outcomeControlled TrialsAlcohol drinkingMedication conditionResearch clinicNaltrexonePsychiatric conditionsSecondary analysisImportant gender differencesTotal abstinenceHeavy drinkingPathologyWomenDrinking outcomes
2006
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
O’Malley S, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. JAMA Internal Medicine 2006, 166: 667-674. PMID: 16567607, DOI: 10.1001/archinte.166.6.667.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAmbulatory CareDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLinear ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsNicotineNicotinic AgonistsSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTreatment OutcomeWeight GainConceptsNicotine patch therapyNicotine patchPatch therapyDouble-blind placebo-controlled trialHigher continuous abstinence ratesLow-dose naltrexone therapyNaltrexone hydrochlorideWeight gainTreatment completersOral naltrexone hydrochlorideOutpatient research centerWeight-concerned smokersContinuous abstinence ratesPlacebo-controlled trialPrimary end pointSecond-line treatmentNicotine replacement therapyNaltrexone augmentationNaltrexone therapyPlacebo groupQuit dateTreat analysisAbstinence ratesReplacement therapySmoking cessation
2005
Do Daily Interactive Voice Response Reports of Smoking Behavior Correspond With Retrospective Reports?
Toll BA, Cooney NL, McKee SA, O'Malley SS. Do Daily Interactive Voice Response Reports of Smoking Behavior Correspond With Retrospective Reports? Psychology Of Addictive Behaviors 2005, 19: 291-295. PMID: 16187808, PMCID: PMC2527779, DOI: 10.1037/0893-164x.19.3.291.Peer-Reviewed Original ResearchConceptsCigarette consumptionSmoking cessation clinical trialTimeline follow-back methodCessation clinical trialSmoking cessation trialCessation trialClinical trialsInteractive voice response systemSmoking behaviorCigarette useVoice response systemTLFBRetrospective reportsTrialsReportIVR systemEntire sampleParticipantsDaily reportsSmokingCompliance